Agios Pharmaceuticals Inc (NASDAQ:AGIO) - Share price


Stock Report

Agios Pharmaceuticals Inc AGIO

Last Price
$48.92

Day Change
1.41|2.97%

As of 02/03/2021
17:57:53 EST | USD
Minimum 15 Minutes Delay.

Last Close47.51
Day Range46.82 - 49.08
Mkt Cap3.41Bil
52-Wk Range27.77 - 58.93
Yield %-
ISINUS00847X1046
Volume717,693
P/E-
P/S16.61
P/CF-11.61

Share Price

Financials
201820192020
More ...
Income Statement
Revenue94.39117.91203.20
Operating Income-362.48-426.33-316.15
Net Income-346.03-411.47-327.37
Basic EPS-6.03-6.86-4.74
Avg. Diluted Shares Outstanding576069
Balance Sheet
Current Assets613.78611.70636.68
Non Current Assets244.68279.04216.28
Total Assets858.46890.74852.95
Current Liabilities93.5092.8994.39
Total Liabilities170.92250.21453.45
Total Equity687.54640.53399.50
Cash Flow
Operating Cash Flow-304.42-370.62-290.76
Capital Expenditure-6.99-12.17-14.91
Free Cash Flow-311.41-382.79-305.67

In millions, except "Basic EPS". Currency is USD.

Company Profile

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Growth

Fiscal Year Ends

December

Employees

562
Key Stats
More ...
Price/Earning TTM-10.02
Price/Book8.28
Price/Sales TTM16.13
Rev Growth (3 year avg)67.79
EPS Growth (3 year avg)-
Operating Margin % TTM-155.59
Net Margin % TTM-161.11
ROE TTM-62.95
Debt/Equity0.24
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.